Robert Kaplan, DO
Family Medicine · Las Vegas, NVNPI 1124101035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,569 and has fallen 68.4% since, to $495 in 2025. Among family medicine clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- AstraZeneca$871
- Amarin Pharma, Inc.$544
- GSK$511
- Sanofi-aventis U.S. LLC$454
- plus $3K from 33 others
Across 59 payments — averaging $29,254 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$993K
- Pfizer$540K
- Noven Pharmaceuticals, Inc.$85K
- Phathom Pharmaceuticals, Inc.$58K
- AstraZeneca$31K
- Braintree Laboratories, Inc.$13K
- plus $6K from 2 others
What the payments were for
- Speaking & faculty fees$4005%
- Food & beverage$7,27895%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $1,066 |
| AbbVie(2 entities) | 33 | $1,028 |
| AstraZeneca | 33 | $871 |
| Amarin Pharma, Inc. | 25 | $544 |
| GSK | 12 | $511 |
| Sanofi-aventis U.S. LLC | 30 | $454 |
| Novo Nordisk | 26 | $415 |
| Lilly USA, LLC | 22 | $383 |
| Pfizer | 17 | $314 |
| Bayer | 27 | $295 |
| Johnson & Johnson | 15 | $231 |
| Livanova USA, Inc. | 3 | $209 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $179 |
| Boehringer Ingelheim | 10 | $175 |
| Abbott | 7 | $128 |
| Arbor Pharmaceuticals, Inc. | 6 | $113 |
| Esperion Therapeutics, Inc. | 6 | $105 |
| Novartis | 5 | $98 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Exact Sciences | 2 | $41 |
| Eisai Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Viatris Specialty LLC | 1 | $28 |
| Cvrx, Inc. | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Gilead | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Dermira, Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Vertiflex, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,698 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 111 | $138,712 |
| OzempicSemaglutide | 40 | $42,005 |
| EliquisApixaban | 30 | $38,757 |
| VascepaIcosapent Ethyl | 40 | $34,228 |
| KerendiaFinerenone | 19 | $27,914 |
| JardianceEmpagliflozin | 18 | $26,648 |
| RybelsusSemaglutide | 14 | $26,126 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $19,049 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $16,924 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $9,777 |
| EntrestoSacubitril/Valsartan | 11 | $5,887 |
| Icosapent Ethyl | 11 | $4,268 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $3,607 |
| Atorvastatin Calcium | 346 | $2,298 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 96 | $1,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $383 | $138,712111 claims |
| Novo NordiskOzempic, Rybelsus | $415 | $68,13154 claims |
| PfizerEliquis | $314 | $38,75730 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $871 | $28,82642 claims |
| BayerKerendia | $295 | $27,91419 claims |
| Boehringer IngelheimJardiance | $175 | $26,64818 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $454 | $16,92412 claims |
| NovartisEntresto | $98 | $5,88711 claims |
| AbbVieSynthroid | $1,028 | $76117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Warren MagnusLas Vegas$70K
- Kimberly AdamsLas Vegas$51K
- Mandeep GillLas Vegas$24K
- Francis JimenezLas Vegas$20K
- Ryan HuangLas Vegas$18K
- Ma Francesca ChamianLas Vegas$17K
- Leo CapobiancoLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.